Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report

BACKGROUND: Nivolumab is a human monoclonal antibody against programmed death-1 (PD-1) that blocks interactions of PD-1 with both PD-L1 and PD-L2 and upregulates tumor antigen-specific T cell to develop appropriate immune response against cancer cells. It has been approved by the US Food and Drug Ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Potluri, Lakshmi Bhavani, Nanjareddy, Sushmitha, Al Sbihi, Ali, Manasrah, Nouraldeen, Smith, William, Sano, Dahlia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364003/
https://www.ncbi.nlm.nih.gov/pubmed/37492791
http://dx.doi.org/10.21037/acr-22-87

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364003/
https://www.ncbi.nlm.nih.gov/pubmed/37492791
http://dx.doi.org/10.21037/acr-22-87

Ejemplares similares